 |
- Last updated refers to the date when our listing for each treatment was last updated.
- ID is our internal ID - starting with VT.
- Min Karnofsky is a general guide to how well you have to function to use this treatment
- For trials that also have a NCT number, you can click that number to pop up the listing from the clinicaltrials.gov website.
|
|
|
|
|
|
Treatment Name: |
|
Phase 1 Study of Azixa (MPC-6827) and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme |
|
|
|
|
|
|
Keywords: |
|
MPC-6827, Carboplatin |
|
|
|
|
Phase: |
|
Phase 1 |
|
|
|
|
|
|
Treatment ID#s: |
|
VT1925
NCT00635557
|
|
|
|
|
Age Group: |
|
Adults Only |
|
|
|
|
|
|
Min Karnofsky Score: |
|
60: Requires occasional assistance but is able to care for most of own needs |
|
|
|
|
Conditions: |
|
Newly Diagnosed: N
Recurrent: Y
Prior Surgery is Allowed
Prior Radiation is Allowed
Prior Chemotherapy is Allowed
|
|
|
|
|
|
|
Last Updated: |
|
08/11/2009 |
|
|
|
|
Tumor Types: |
|
Glioblastoma Multiforme |
|
|
|
|
|
|
|
Comments: |
|
Azixa (MPC-6827) is a novel small molecule inhibitor of microtubule formation [1] that has demonstrated the ability to inhibit tumor growth in nonclinical testing, with activity in animal models of human melanoma and cancers of the ovary, breast, prostate, colon and pancreas [4]. In nonclinical testing, Azixa has been equally active against multiple drug resistant cancers as with susceptible tumors [2], unlike many of the current options in cancer chemotherapy, a limitation that represents a significant unmet medical need.
In mice, the pharmacokinetics of Azixa indicated that the drug distributed rapidly into the brain. The concentration of Azixa in brain tissue was approximately 14 times higher than the plasma concentration and, and at that level, it easily exceeds the concentration required to activate caspase and induce the cancer cell killing apoptosis process in cancer cells [1,3]. Importantly, Azixa was cleared from the brain at a rate similar to that observed from blood [3]. This suggests a special opportunity to study anti-tumor activity in patients with primary brain tumors and brain metastases that currently cannot be treated effectively with chemotherapy due to ineffective drug penetration into the brain. |
|
|
|
|
|
|
Treatment Type: |
|
Chemotherapy. |
|
|
|
|
Contact: |
|
The Angeles Clinic and Research Institute
Omid Hamid, MD
Contact: Audrey Roque-Tayag
11818 Wilshire Boulevard, Suite 200
Los Angeles, CA 90025
Phone:310-231-2183
Click here to send an email
Emory University
Jeffrey Olsen
Contact: Dr. Jeffrey Olsen
1327 Clifton Road, NE
Atlanta, GA 30322-
Phone:(404)778-5344
Fax: (404)778-5121
Click here to send an email
Mount Sinai School Of Medicine
Robert Aiken, MD
Contact: Mary-Catherine George,
New York, NY 10029
Phone:212-241-0784
Click here to send an email
MD Anderson Cancer Center
John F. de Groot, MD
Department of Neuro-Oncology
Contact: Be Pei, Department of Neuro Oncology - Unit 431
1515 Holcombe Blvd
Houston, TX 77030
Phone:713-792-8560
Click here to send an email
Huntsman Cancer Institute
Clinical Trials Office - Huntsman Cancer Institute
University of Utah
Salt Lake City, UT 84112
Phone:801-581-4477
Click here to send an email |
|
|
|
|
